MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cca.2026.121248

Медицинская библиотека · Clinica chimica acta; international journal of clinical chemistry · 2026

Specific serum metabolites can differentiate severe and mild human traumatic brain injury.

Shi Lei, Wang Zhuonan, Zhang Jie, Zheng Ping, Bai Lijun

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Traumatic Brain Injury (TBI) is a prevalent neurological condition with significant public health implications. The heterogeneity in TBI's pathophysiology presents challenges in diagnosis and prognosis, highlighting the need for sensitive and specific biomarkers. Metabolomic studies have emerged as a promising approach to identify such biomarkers.

OBJECTIVE

This study aimed to define the serum metabolome in patients with acute TBI and to identify metabolites that could differentiate severe from mild TBI, potentially serving as novel biomarkers for diagnosis and prognosis.

METHODS

We conducted a metabolomic analysis on 12 severe TBI patients, 33 mild TBI patients, and 30 healthy controls. Blood samples were collected within 24 h post-injury, and metabolomic profiling was performed using LC-MS/MS and GC-MS. Data preprocessing and statistical analysis were conducted using Progenesis QI software, followed by Random Forest analysis and ROC curve assessments for metabolite selection and validation.

RESULTS

The serum metabolome of TBI patients significantly differed from non-TBI patients, with distinct metabolic signatures correlating with injury severity. Methoxyamine was identified as a potential biomarker, showing increased levels in severe TBI compared to mild TBI and healthy controls. In the random forest analysis, methoxyamine was ranked among the top discriminating metabolites between severe and mild TBI, achieving an AUC of 0.8333 in the testing dataset. Network toxicology and molecular docking suggested a potential interaction between methoxyamine and HSP90AA1, a protein associated with TBI severity as well.

CONCLUSION

Our findings indicate that specific serum metabolites, particularly methoxyamine, may serve as novel biomarkers for differentiating severe from mild TBI. Further research is warranted to explore their potential as therapeutic targets and their role in TBI pathophysiology.

Для цитирования: Shi Lei, Wang Zhuonan, Zhang Jie, Zheng Ping, Bai Lijun. Specific serum metabolites can differentiate severe and mild human traumatic brain injury.. Clinica chimica acta; international journal of clinical chemistry. 2026. DOI: 10.1016/j.cca.2026.121248.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.